Thompson Siegel & Walmsley LLC Acquires 2,986 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Thompson Siegel & Walmsley LLC lifted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 195,743 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,986 shares during the period. Thompson Siegel & Walmsley LLC owned approximately 0.93% of ANI Pharmaceuticals worth $12,465,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in ANIP. Allspring Global Investments Holdings LLC grew its position in ANI Pharmaceuticals by 287.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock worth $1,471,000 after buying an additional 15,790 shares in the last quarter. Great Lakes Advisors LLC raised its position in ANI Pharmaceuticals by 67.1% during the fourth quarter. Great Lakes Advisors LLC now owns 48,252 shares of the specialty pharmaceutical company’s stock valued at $2,661,000 after purchasing an additional 19,378 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in ANI Pharmaceuticals by 106.9% during the first quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock worth $1,434,000 after purchasing an additional 10,716 shares during the last quarter. Wakefield Asset Management LLLP purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth about $979,000. Finally, Sequoia Financial Advisors LLC bought a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $600,000. Institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ANIP. Truist Financial reaffirmed a “hold” rating and issued a $60.00 target price (down previously from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $77.75.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $58.51 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. ANI Pharmaceuticals, Inc. has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The firm has a market cap of $1.23 billion, a PE ratio of 36.57 and a beta of 0.71. The business has a 50 day moving average price of $61.39 and a 200-day moving average price of $63.88.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.07. The business had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm’s revenue for the quarter was up 18.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.06 EPS. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

Insider Transactions at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 14,257 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total transaction of $900,472.12. Following the transaction, the chief operating officer now owns 635,363 shares in the company, valued at approximately $40,129,527.08. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, COO Muthusamy Shanmugam sold 14,257 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total value of $900,472.12. Following the sale, the chief operating officer now directly owns 635,363 shares in the company, valued at approximately $40,129,527.08. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $63.44, for a total value of $1,268,800.00. Following the transaction, the senior vice president now owns 193,226 shares of the company’s stock, valued at approximately $12,258,257.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,757 shares of company stock worth $4,075,585. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.